Referred to the House Committee on Energy and Commerce.
The bill would add a new requirement to the Federal Food, Drug, and Cosmetic Act directing the Secretary of Health and Human Services to issue regulations (within one year) that require manufacturers to provide standardized, FDA‑approved, paper patient medication information (PMI) with each prescription for drugs subject to section 503(b)(1). The PMI must be scientifically accurate, non‑promotional, in plain language (with graphics where applicable), use standardized format, font size, and color, and include specified content such as indications, directions, warnings, interactions, subpopulation data, manufacturer contact, and a link to FDA adverse event reporting.
Whether the federal government should mandate universal paper distribution versus allowing electronic delivery or opt‑in/opt‑out approaches (conservative opposition vs. liberal/centrist support).
Relative to its intended legislative type, this bill establishes substantive changes to the FD&C Act by creating a new statutory requirement for standardized, printed patient medication information and a companion misbranding provision, and it assigns administrative rulemaking responsibility to the Secretary with a one-year deadline.
The bill would add a new requirement to the Federal Food, Drug, and Cosmetic Act directing the Secretary of Health and Human Services to issue regulations (within one year) that require manufacturers to provide standardized, FDA‑approved, paper patient medication information (PMI) with each prescription for drugs subject to section 503(b)(1).
The PMI must be scientifically accurate, non‑promotional, in plain language (with graphics where applicable), use standardized format, font size, and color, and include specified content such as indications, directions, warnings, interactions, subpopulation data, manufacturer contact, and a link to FDA adverse event reporting.
Regulations must provide for timely review and updates, be developed based on documented patient research demonstrating improved understanding and adherence, and ensure an "adequate supply" (one printed PMI per prescription including bulk packaging).
On content alone, the bill advances a non-ideological, consumer-safety objective that could attract support, but it also imposes wide-reaching, administratively intensive mandates (paper-only standardized PMI for every prescription) and triggers enforcement via misbranding. Those features create predictable industry resistance and implementation challenges. The absence of transitional mechanisms, cost offsets, or clear regulatory capacity planning reduces near-term prospects without substantive amendments or compromise.
Relative to its intended legislative type, this bill establishes substantive changes to the FD&C Act by creating a new statutory requirement for standardized, printed patient medication information and a companion misbranding provision, and it assigns administrative rulemaking responsibility to the Secretary with a one-year deadline.
Whether the federal government should mandate universal paper distribution versus allowing electronic delivery or opt‑in/opt‑out approaches (conservative opposition vs. liberal/centrist support).
These are examples from the analysis, not a ranked list of the most-affected groups.
Whether the federal government should mandate universal paper distribution versus allowing electronic delivery or opt‑in/opt‑out approaches (conservative opposition vs. liberal/centrist support).
A mainstream progressive would likely view the bill as a patient‑protection measure that improves access to clear, standardized medication information—especially for people without reliable internet access.
They would welcome the focus on plain language, inclusion of safety information for subpopulations, and a mandate for paper copies to reduce adverse drug events.
They may, however, want stronger guarantees for accessibility (translations, low‑literacy design, formats for visually impaired people), pharmacist counseling, and enforcement mechanisms to ensure manufacturers do not minimize risks.
A moderate/centrist would generally support the goal of improved patient safety and access to understandable drug information, while emphasizing practical implementation concerns.
They would appreciate the bill’s reliance on FDA rulemaking and evidence‑based research to define format and content, but be attentive to administrative costs, compliance burdens, and timeline feasibility.
They would likely urge measured, phased implementation and clarity around which products and entities are responsible for compliance.
A mainstream conservative would likely be skeptical of the new federal mandate requiring standardized paper PMI, viewing it as additional regulatory burden and potential source of increased costs.
They would raise concerns about one‑size‑fits‑all federal specifications (format, color, font), the manufacturing and distribution costs of supplying paper for every prescription, and the expansion of misbranding liability.
They would prefer market‑based or state solutions, optional paper copies upon request, or allowing electronic delivery with opt‑out options rather than a blanket federal paper mandate.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, the bill advances a non-ideological, consumer-safety objective that could attract support, but it also imposes wide-reaching, administratively intensive mandates (paper-only standardized PMI for every prescription) and triggers enforcement via misbranding. Those features create predictable industry resistance and implementation challenges. The absence of transitional mechanisms, cost offsets, or clear regulatory capacity planning reduces near-term prospects without substantive amendments or compromise.
The bill has not accumulated any surfaced votes yet.
Whether the federal government should mandate universal paper distribution versus allowing electronic delivery or opt‑in/opt‑out approaches…
On content alone, the bill advances a non-ideological, consumer-safety objective that could attract support, but it also imposes wide-reach…
Relative to its intended legislative type, this bill establishes substantive changes to the FD&C Act by creating a new statutory requirement for standardized, printed patient medication information and a companion misbr…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.